A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age with Attention Deficit Hyperactivity Disorder
Clinical Trial Grant
Administered By
Psychiatry & Behavioral Sciences
Awarded By
Sunovion Pharmaceuticals, Inc
Start Date
March 1, 2015
End Date
July 29, 2015
Administered By
Psychiatry & Behavioral Sciences
Awarded By
Sunovion Pharmaceuticals, Inc
Start Date
March 1, 2015
End Date
July 29, 2015